ArticlePeerJ2026
A retrospective investigation of the platelet-to-lymphocyte ratio as a potential indicator in early rheumatoid arthritis.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The platelet-to-lymphocyte ratio (PLR) has been suggested as a biomarker for inflammation and disease activity in rheumatoid arthritis (RA). However, current findings on its correlation with the Disease Activity Score 28 (DAS28) remain inconsistent. This study aimed to explore the correlation between PLR and DAS28. Methods: This retrospective study analyzed 433 consecutive inpatients with early RA at Xingtai People's Hospital between January 2022 and January 2024. Of these, 72.06% were women, with a mean age of 52.52 ± 14.20 years. All patients met the 2010 American College of Rheumatology/European League Against Rheumatism criteria and had symptoms <2 years. To further explore the association between the PLR and the DAS28, multiple regression analyses were conducted, followed by generalized additive models. Results: After adjusting for potential confounding factors, we found that for every 50-unit increase in PLR, DAS28 based on erythrocyte sedimentation rate (ESR) increases by 0.126 ( Conclusion: This study revealed a threshold effect: in patients with early RA (ERA), PLR is positively associated with DAS28-ESR and DAS28-CRP only when PLR is below 254. Above that level, the pattern may not hold, illustrating a nonlinear relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.